A PHASE 2 MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF T-817MA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE OR MILD ALZHEIMER’S DISEASE
Ámbito: Internacional
Fecha: 01/02/2018
|